Claims:

1. A liquid dosage form of Imatinib comprising:

   about 0.01% to about 25% w/v of Imatinib or a pharmaceutically acceptable salt thereof;

   about 25% to about 60% w/v of a solvent or co-solvent or solubilizer; selected from group consisting of dichloromethane, acetonitrile, ethyl acetate, acetone, propylene carbonate, glycerin, coconut fatty acid diethanolamide, medium and/or long chain fatty acids or glycerides, monoglycerides, diglycerides, triglycerides, structured triglycerides, soyabean oil, peanut oil, corn oil, corn oil monoglycerides, corn oil diglycerides, corn oil triglycerides, polyethylene glycol, caprylocaproylmacroglycerides, caproyl 90, propylene glycol, polyoxyethylenesorbitan fatty acid esters, polyoxyethylene castor oil derivatives, castor oil, cottonseed oil, olive oil, safflower oil, peppermint oil, coconut oil, palm seed oil, beeswax, oleic acid, methanol, ethanol, isopropyl alcohol, butanol, acetone, methyl isobutyl ketone, methyl ethyl ketone or any combination thereof;

   about 0.01% to about 10% w/v of a preservative selected from group consisting of Ethanol, Chlorobutanol, Phenoxyethanol, Potassium benzoate, Benzyl alcohol, Benzoic acid, Potassium sorbate, Sorbic acid, Benzalkonium chloride, Benzethonium chloride, Cetrimonium bromide, Cetylpyridinium chloride, Bronopol, Chlorbutol, Chlorocresol, Cresol, Butylparaben or salt thereof, Methylparaben or salt thereof, Propylparaben or salt thereof, Ethylparaben or salt thereof, Phenol, Thymol, Phenylethanol, Sodium benzoate, Propylene glycol, Glycerin, Chloroform or any combination thereof;

   a pH modifying agent or buffering agent in a quantity sufficient to adjust the pH of the liquid dosage form to a desired pH; and

   a vehicle in a quantity sufficient to bring the final volume of the liquid dosage form to the desired volume.

2. The liquid dosage form of claim 1, wherein the solvent or co-solvent or solubilizer is Glycerin.

3. The liquid dosage form of claim 1, wherein the pharmaceutically acceptable salt of imatinib is mesylate.

4. The liquid dosage form of claim 1, further comprising about 0.01% to about 15% w/v of a sweetening agent.

5. The liquid dosage form of claim 1, further comprising about 0.01% to about 5% w/v of a flavouring agent.

6. The liquid dosage form of claim 1, wherein the pH is from about 2.0 to about 7.0.

7. The liquid dosage form of claim 1, wherein the pH modifying agent or buffering agent is selected from the group consisting of Acetic acid, Adipic acid, Ammonium carbonate, Ammonium hydroxide, Ammonium phosphate, Boric acid, Citric acid, Diethanolamine, Fumaric acid, Hydrochloric acid, Malic acid, Nitric acid, Propionic acid, Potassium acetate, Potassium bicarbonate, Potassium chloride, Potassium citrate, Potassium metaphosphate, Potassium phosphate, Sodium acetate, Sodium bicarbonate, Sodium borate, Sodium carbonate, Sodium chloride, Sodium citrate, Sodium glycolate, Sodium hydroxide, Sodium lactate, Sodium phosphate, Sodium proprionate, Succinic acid, Sulfuric acid, Tartaric acid, Triethylamine, Triethanolamine, Tromethamine, Trolamine or any combination thereof.

8. A liquid dosage form of Imatinib comprising:
   about 0.01% to about 25% w/v of Imatinib mesylate;
   about 25% to about 60% w/v of Glycerin;
   about 0.01% to about 10% w/v of Sodium benzoate;
   about 0.01% to about 10% w/v of Liquid Maltitol;
   Citric acid in a quantity sufficient to adjust the pH of the liquid dosage form to a desired pH; and
   Water in a quantity sufficient to bring the final volume of the liquid dosage form to the desired volume.

9. The liquid dosage form of claim 8, wherein the pH is from about 2.0 to about 7.0.

10. A process for the preparation of a liquid dosage form of Imatinib comprising:
about 0.01% to about 25% w/v of Imatinib mesylate;
about 25% to about 60% w/v of Glycerin;
about 0.01% to about 10% w/v of Sodium benzoate;
about 0.01% to about 10% w/v of Liquid Maltitol;
about 0.01% to about 5% w/v of Acesulfame or the potassium salt thereof;
about 0.01% to about 5% w/v of strawberry flavour citric acid in a quantity sufficient to adjust the pH of the liquid dosage form from about 2.0 to about 7.0; and
water in a quantity sufficient to bring the final volume of the liquid dosage form to the desired volume,
comprising following steps:
(a) Glycerin, Sodium benzoate and Liquid maltitol are added in water;
(b) Add Acesulfame or the potassium salt thereof in step (a) followed by addition of Imatinib mesylate;
(c) Citric acid is added in step (b) to adjust the pH from about 2.0 to about 7.0 followed by addition of strawberry flavor; and
(d) Adjust the total volume to the desired quantity with water.